These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21565521)

  • 21. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
    Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
    Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients.
    Rajan SS; Stearns SC; Lyman GH; Carpenter WR
    Breast Cancer Res Treat; 2011 Nov; 130(1):255-66. PubMed ID: 21584667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.
    O'Regan RM; Von Roenn JH; Carlson RW; Malik U; Sparano JA; Staradub V; Khan S; Jovanovic B; Morrow M; Gradishar WJ
    Clin Breast Cancer; 2005 Jun; 6(2):163-8. PubMed ID: 16001995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of Taxotere in adjuvant chemotherapy of breast cancer].
    Besova NS
    Vopr Onkol; 2011; 57(5):651-7. PubMed ID: 22238938
    [No Abstract]   [Full Text] [Related]  

  • 27. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer].
    Kawabata H; Iwatani T; Makuuchi R; Miura D; Suzuki N; Nakazawa H
    Gan To Kagaku Ryoho; 2010 May; 37(5):835-9. PubMed ID: 20495312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
    Weycker D; Edelsberg J; Kartashov A; Barron R; Lyman G
    Chemotherapy; 2012; 58(1):8-18. PubMed ID: 22343254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
    Eiermann W; Pienkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press M; Sauter G; Lindsay MA; Riva A; Buyse M; Drevot P; Taupin H; Mackey JR
    J Clin Oncol; 2011 Oct; 29(29):3877-84. PubMed ID: 21911726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
    Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
    Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Medical treatment of early breast cancer: chemotherapy].
    Ejlertsen B; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
    Trent JC; Valero V; Booser DJ; Esparza-Guerra LT; Ibrahim N; Rahman Z; Vernillet L; Patel S; David CL; Murray JL; Cristofanilli M; Hortobagyi GN
    Clin Cancer Res; 2003 Jul; 9(7):2426-34. PubMed ID: 12855614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
    Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
    Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
    Yardley DA; Burris HA; Farley CP; Barton JH; Peacock NW; Spigel DR; Greco FA; Hainsworth JD
    Clin Breast Cancer; 2008 Jun; 8(3):242-8. PubMed ID: 18650154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients.
    Chow LWC; Biganzoli L; Leo AD; Kuroi K; Han HS; Patel J; Huang CS; Lu YS; Zhu L; Chow CYC; Loo WTY; Glück S; Toi M
    Asia Pac J Clin Oncol; 2017 Dec; 13(6):372-378. PubMed ID: 28371190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.